Key result
Urothelin A promoted PKG1α oxidation and improved ventricular relaxation and exercise capacity in a mouse model of heart failure with preserved ejection fraction.
Why the study?
Does urothelin A improve cardiac function and exercise capacity in a mouse model of HFpEF?
Does urothelin A improve cardiac function and exercise capacity in a mouse model of HFpEF?
Answers are grounded in this paper and cite their sources.
Promoting PKG1α disulfide bonding through oxidation with agents like urothelin A may offer a novel, alternative therapeutic pathway to classical cGMP-mediated PKG1 activation for HFpEF.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Robert M. Blanton (2026) conducted an editorial in Heart failure with preserved ejection fraction (HFpEF). Urothelin A was evaluated. Urothelin A promoted PKG1α oxidation and improved ventricular relaxation and exercise capacity in a mouse model of heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: